Session Title : Guided by evidence: a unified approach to CKD, diabetes and HF management
Organized By : Bayer AG
Session Description : This spotlight session will explore the importance of targeting albuminuria as a modifiable CKD and cardiovascular risk factor and examine finerenone’s role as a foundational therapy within a multi-pillar CKM approach. A case-based panel discussion will address real-world barriers to delivering comprehensive cardiorenal care and provide practical insights to help clinicians integrate these principles into multidisciplinary practice.
Learning Objectives :